Omnicell Q1 2026 revenue rises 15% to $310 million; raises 2026 EBITDA and EPS guidance
Omnicell reported first-quarter 2026 total revenue of $310 million, up 15% from a year earlier, and GAAP net income of $11 million, or $0.25 per diluted share, compared with a net loss of $7 million, or $0.15 per share, in the first quarter of 2025. The company raised its full-year 2026 non-GAAP EBITDA and non-GAAP earnings per share guidance, citing first-quarter profitability and spend discipline.
Key points
- Total revenue of $310 million, up $40 million, or 15%, from the first quarter of 2025.
- GAAP net income of $11 million ($0.25 per diluted share) versus a GAAP net loss of $7 million ($0.15 per share) a year earlier.
- Full-year 2026 non-GAAP EBITDA guidance raised to $153 million-$168 million; non-GAAP EPS guidance raised to $1.80-$2.00.
- Cash and cash equivalents of $239 million as of March 31, 2026; second-quarter 2026 total revenue guidance of $307 million-$313 million.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:55 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 28, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.